This study is a randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with Bronchiectasis.
To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at firstname.lastname@example.org or phone 6151 0888.
Eligibility & Requirements
- Aged 18 to 85 years
- Diagnosis of bronchiectasis confirmed by CT scan
- Exacerbations requiring antibiotic treatment in the last 12 months
- Current sputum producers with a history of chronic expectoration, able to provide spontaneous sputum at Screening
- The study duration is approximately 58 weeks. It involves up to 11 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and up to 5 telemedicine phone calls.